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Bello*[a] 
 
A COMBINE analysis to derive QSAR models that help rationalize the 
determinants of binding affinity for inhibitors of the third enzyme of the 
shikimic acid pathway, type II dehydroquinase (DHQ2), is reported. 
Independent COMBINE models were derived for Helicobacter pylori 
and Mycobacterium tuberculosis DHQ2, which is an essential enzyme 
in these pathogenic bacteria that has no counterpart in human cells. 
These studies quantify the importance of the hydrogen bonding 
interaction of the ligands with the water molecule involved in the 
enzymatic mechanism and highlight important differences in the 
ligand interactions with the interface pocket close to the active site 
that could provide guides for future inhibitor designs. 
 
Introduction 
The shikimic acid pathway that is present in bacteria, fungi, plants, 
and in certain apicomplexan parasites, but it is absent in 
mammals, is considered an attractive target for the development 
of new antimicrobials and herbicides.[1,2] In recent years a great 
deal of effort has been focused on the development of inhibitors 
of the enzymes involved in this route. Among them, the third 
enzyme in the pathway, the type II dehydroquinase (3-
dehydroquinate dehydratase, EC 4.2.1.10, DHQ2), has generated 
particular interest because it is essential in important pathogenic 
bacteria such as, Mycobacterium tuberculosis, the causative 
agent of tuberculosis, and Helicobacter pylori, the causative 
agent of gastric and duodenal ulcers, which has also been 
classified as a type I carcinogen.[3] 
DHQ2 catalyzes the reversible dehydration of 3-dehydroquinic 
acid (1) to form 3-dehydroshikimic acid (2) (Scheme 1). The 
enzymatic conversion is initiated by an essential tyrosine of the 
active site that removes the pro-S hydrogen from C2 of 1.[4,5] The 
elimination proceeds through a stepwise E1CB mechanism
[4] 
involving an enol intermediate 3, which is stabilized by a 
conserved water molecule. The final step is the acid-catalyzed 
elimination of the C1 hydroxyl group  a reaction mediated by a 
conserved histidine acting as a proton donor. 
As a result of these investigations, a large number of competitive 
reversible inhibitors have been developed that include analogs of 
the natural substrate, e.g. compounds 4,[6] and mimetics of the 
intermediate of the enzyme-catalyzed reaction, e.g. compounds 
5[7-19] and the bicyclic derivatives 6[20] (Figure 1).[21,22] In addition, 
crystal structures of several enzyme-inhibitor binary complexes 
with both types of inhibitors have also been described.[7-9,20,23-25] 
The resolution of these crystal structures has been very important 
to understand the role of the substituents 1R4R in compounds 4–
6, in particular, their interaction with key residues responsible for 
catalysis, both located in the flexible loop that closes over the 
active site upon substrate binding. Besides, a detailed knowledge 
of the contribution of each active site residue to the observed 
inhibition activity would provide valuable information that could 
help improve our understanding of some of the determinants of 
binding affinity and guide further inhibitor design. For this purpose, 
COMparative BINding Energy (COMBINE) analysis, a 
chemometric method that relies on a number of three-
dimensional complexes to calculate, decompose and weigh 
residue-based ligand-receptor interaction energies(both van der 
Waals and electrostatic),[26] has become particularly useful in the 
study of quantitative structure-activity relationships (QSAR). It has 
been successfully applied to protein-ligand,[27-31] RNA-ligand,[32] 
protein-DNA[33] and protein-peptide complexes.[34] The data matrix 
generated by following this approach is then subjected to 
multivariate statistical analysis to try and correlate the computed 
energy components with experimental measures of activity or 
affinity using Partial Least Squares (PLS) analysis. 
In the following we show how COMBINE analysis was useful to 
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gain critical information regarding the interactions in the active 
site of a series of competitive reversible inhibitors of DHQ2 
enzymes from H. pylori (DHQ2-Hp) and M. tuberculosis (DHQ2-
Mt) and derive QSAR models that aid in the rationalization of the 
determinants of binding affinity and in understanding the 
differences between both enzymes. 
 
Scheme 1. Enzymatic conversion of 3-dehydroquinic acid (1) to 3-
dehydroshikimic acid (2) catalyzed by DHQ2. The reaction proceeds via an enol 
intermediate 3. Relevant residues are indicated (the numbering corresponds to 
M. tuberculosis). 
 
Figure 1. Competitive reversible inhibitors of DHQ2. 2-alkyl ketones 4 are 
substrate analogs and compounds 5 and 6 are mimetics of the intermediate of 
the enzyme-catalyzed reaction. 
Results and Discussion 
The COMBINE analysis with the H. pylori enzyme was carried out 
on 54 enzyme-inhibitor complexes modeled after eight DHQ2-
Hp/ligand co-crystal structures (PDB accession codes: 2WKS,[7] 
1J2Y,[35] 2C4W,[24] 2C57,[24] 2XB9,[23] 2XDA,[20] 2C4V[24] and 
2XD9[20]). The inhibitors covered an activity range, expressed as 
pKi, between 3.4 and 7.0. The best cross-validated PLS model 
had four latent variables (supporting information). For the DHQ2-
Mt enzyme, 63 compounds covering an activity range between 
3.7 and 7.6 pKi units, and 13 crystallographic binary DHQ2-
Mt/ligand complexes (PDB accession codes: 1H0R,[36] 1H0S,[36] 
2Y71,[8] 2Y76,[8] 2Y77,[8] 2XB8,[23] 3N59,[9] 3N8K,[9] 3N76,[9] 
3N87,[9] 3N8N,[9] 3N7A[9] and 1H05[37]) were employed. For this 
enzyme, the best cross-validated PLS model has six latent 
variables (supporting information). In both studies, the pKi values 
proved to be highly correlated with a set of weighted ligand-
residue interaction energies (r2 = 0.83 ± 0.07 and 0.88 ± 0.05, 
respectively, in fitting and q2 = 0.73 ± 0.11 and 0.71 ± 0.11, 
respectively, in cross-validation; Figure 2).  
 
Figure 2. Correlation between experimental pKi values and those calculated 
using the COMBINE QSAR models for DHQ2-Hp (top, 4 latent variables) and 
DHQ2-Mt (bottom, 6 latent variables). 
The PLS pseudo-coefficients (hereafter coefficients) for the 
calculated van der Waals and electrostatic interactions 
corresponding to the best model of each enzyme are shown in 
Figure 3 and summarized in Table 1. 
The sign and the magnitude of the PLS coefficient assigned to an 
energy term multiplied by the corresponding energy value reveals 
the relative importance of each residue in accounting for the 
observed differences in binding affinity. Since inhibition constants 
(i.e. Ki, or dissociation constants of the enzyme-inhibitor 
complexes) can be directly related to the free energy of binding to 
the enzyme as                        , the chemometric 
meaning of the values obtained is that the larger a negative PLS 
coefficient multiplying a favorable interaction energy (negative 
value), the greater the pKi and vice versa. 
In general, the COMBINE analysis for the DHQ2-Hp enzyme 
identifies that the electrostatic and hydrogen bonding interaction 
with the essential water molecule (WATe), is the most significant 
contribution to the inhibition potency. This study also shows that 
van der Waals interactions involving the active site residues 
Asn10, Met13, Leu14, Tyr22, Leu103, His102 and Gly78, 
together with residues Gln63* and Ala90* from a symmetry-
related neighboring enzyme subunit, are those that contribute 
most significantly to explaining the differences in inhibitory 
potency as these residues have the largest PLS coefficients 
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assigned to their van der Waals interactions with the ligands. For 
DHQ2-Mt, the COMBINE analysis suggests that the potency of 
the inhibitors is enhanced by promoting van der Waals 
interactions with active site residues Tyr24, Leu13, Leu16, Ile102, 
Gly77, Asn75 and His101, and also with residues Ala91* and 
Glu92* from a neighboring subunit, as well as by electrostatic 
and/or hydrogen bonding interactions with the essential water 
molecule (WATe) and with a crystallographic water molecule 
(WATc) located near Arg108 and Tyr24. In both cases, these key 
interactions can be organized into five key pockets as follows 
(Figure 4): 
 
Figure 3. Plot of normalized PLS coefficients of the van der Waals (top) and electrostatic (bottom) interactions in the COMBINE models for DHQ2-Hp (left, 4 latent 
variables) and DHQ2-Mt (right, 6 latent variables). The residues with the highest coefficients have been labeled. WATE and WATC stand for the essential and 
crystallographic water molecules, respectively.   
Loop  Essential tyrosine. The COMBINE analysis for DHQ2-Hp 
reveals that the interaction with Tyr22, which has a PLS 
coefficient of 0.32, is one of the most relevant interactions for 
enhancing inhibition of this enzyme. Tyr22, as well as Arg17, has 
been identified by chemical modification and site-directed 
mutagenesis studies as being essential for enzyme activity.[42,43] 
Both residues are located in the flexible loop that closes over the 
active site upon substrate binding. Molecular dynamics (MD) 
simulation studies suggested that the side chain of Tyr22 must be 
perpendicular to the cyclohexane ring of the natural substrate for 
proton abstraction.[23,25] The favorable interaction of the aromatic 
rings of the ligands with the Tyr22 side chain prevents its 
appropriate orientation for catalysis. Such favorable interaction 
causes a drastic reduction of the loop flexibility that is essential 
for enzyme function. Comparison of the PLS coefficients for the 
essential tyrosine obtained for both enzymes shows that the van 
der Waals interaction with this residue is less significant for 
DHQ2-Mt. We consider that these differences are due to the 
distinct loop flexibility and motion in the two enzymes which we 
have studied in detail.[25] MD simulation results suggest that the 
essential arginine of this loop has a crucial role in controlling the 
position and appropriate orientation of Tyr22 whereas in DHQ2-
Mt this tyrosine side chain motion is not controlled by the 
essential arginine. Instead, its position could be mainly controlled 
by the interaction with the aromatic moiety of the ligand. These 
differences make DHQ2-Hp particularly sensitive to changes 
introduced at the C2 position of the natural substrate because the 
loop should be less able to accommodate these changes than the 
equivalent loop in DHQ2-Mt. Moreover, for this latter enzyme, the 
COMBINE analysis reveals an unfavorable contribution of the 
electrostatic interaction with Arg108 (a PLS coefficient of +0.30). 
This residue has a key role in the function of the Tyr24 residue. 
When the substrate binds to the enzyme, the loop is closed over 
and a strong hydrogen bonding interaction between the phenolic 
OH of Tyr24 and the conserved Arg108 is formed. Regardless of 
the appropriate (catalysis) or inappropriate (inhibition) 
conformation of the tyrosine side chain, the hydrogen bonding 
interaction between both residues is crucial. Hence, this 
COMBINE study predicts that those ligands having a favorable 
electrostatic interaction with Arg108, for instance through the C1 
carboxylate group, will show lower affinity for the enzyme. The 
fact that a similar situation was not predicted for DHQ2-Hp can be 
explained by considering once again the differences in loop 
motion and flexibility of both enzymes. In fact, in all the available 
DHQ2-Hp crystal structures, the essential tyrosine’s side chain 
establishes a strong hydrogen bonding interaction with the 
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guanidinium group of Arg109. In contrast, for DHQ2-Mt, this 
hydrogen bonding interaction is not always observed, and in 
some cases, the position of this residue has not been located in 
the electron density map. 
 
Table 1. Selection of the PLS pseudo-coefficients assigned to the van der 
Waals and electrostatic interaction energies obtained from the COMBINE 
analyses of DHQ2-Hp and DHQ2-Mt.
[a]
 
H. pylori M. tuberculosis 
Residue vdW Elec Residue vdW Elec 
Tyr22 –0.32 -- Tyr24 –0.19 –0.19 
Met13 –0.15 -- Arg108 -- 0.30 
Gln63* –0.14 --    
Asp89* 0.17 0.28 Asp88* 0.23 0.16 
Ala90* –0.20 -- Ala91* –0.21 -- 
Leu93* 0.13 -- Glu92* –0.26 -- 
Leu14 –0.26 -- Leu13 –0.23 -- 
   Leu16 –0.15 -- 
Leu103 –0.11 -- Ile102 –0.28 -- 
Gly78 –0.24 -- Gly77 –0.38 -- 
   Pro11 0.12 –0.14 
Asn10 -- –0.12 Asn12 -- 0.26 
   Asn75 –0.22 -- 
His102 –0.13  His101 –0.16 -- 
WATE –0.45 –0.21 WATE –0.56 –0.62 
   WATC –0.31 0.15 
[a] Only PLS pseudo-coefficients with absolute values greater than 0.1 are 
displayed. WATE and WATC are the essential and crystallographic water 
molecules, respectively. 
 
Interface between chains. This is a very important pocket[9] of the 
enzyme that reveals significant differences between both 
enzymes and whose contribution can be now quantified. For 
DHQ2-Hp, the results indicate that the van der Waals or 
hydrogen bonding interactions of the ligands with Met13 and two 
residues of a symmetry-related neighboring subunit, Gln63* and 
Ala90*, would improve their inhibition potency. For the latter 
residues, negative PLS pseudo-coefficients of 0.15, 0.14 and 
0.20, were assigned (Figure 4a). On the contrary, van der Waals 
interactions with residues Leu93* and Asp89*, also located in the 
neighboring subunit, are identified as unfavorable, showing 
positive PLS pseudo-coefficients of 0.13 and 0.17, respectively. 
For DHQ2-Mt, a negative coefficient for the favorable van der 
Waals interaction, which is quantitatively similar to that assigned 
to Tyr24, with residues Ala91* and Glu92* located in the 
neighboring subunit is identified (Figure 4c). For the latter 
residues, negative PLS pseudo-coefficients of 0.21 and 0.26, 
respectively, were obtained. 
A comparison of the amino acid sequences of both enzymes 
reveals that there are important differences in the type of residues 
located in this pocket (see supporting information). The pocket is 
more polar in DHQ2-Mt than in DHQ2-Hp as it is made up of 
His63*, Glu92*, Asp67*, Arg15, Asp53, and Asn12 residues in the 
former and Ile59*, Gln63*, Leu93*, Val66*, Met13, Asn53, Asn10 
and Asn12 in the latter. This explains the fact that, in some cases, 
the same ligand shows marked differences in its interaction with 
both enzymes. These COMBINE analyses quantify these 
differences and provide guides for further inhibitor design. Thus, 
for DHQ2-Hp, these results suggest that those compounds 
functionalized with a flexible chain located at the bottom of the 
interface might provide more potent inhibitors, since this would 
enhance their interaction with residues Gln63* and Ala90* and 
avoid contacts with Asp89* and Leu93* which are the residues 
located at the top of the interface that this COMBINE study 
identifies as unfavorable. For DHQ2-Mt, the results suggest that 
the inhibitory potency of the ligands might be enhanced by 
establishing favorable van der Waals interactions with Glu92*, 
which is located at the entrance to the interface between two 
neighboring subunits and not with the side chain residues at the 
bottom of the interface as in DHQ2-Hp. In common with the 
analysis on DHQ2-Hp, COMBINE identifies any contacts with the 
Asp88* located in the neighboring subunit as unfavorable. For 
both enzymes, this conserved residue is involved in the 
recognition of the hydroxyl group at the C4 position in both the 
natural substrate and the reaction intermediate. 
C2 binding pocket. This is a key region of the active site for ligand 
binding. For DHQ2-Hp, it is lined by residues Leu14, Gly78 and 
Leu103, which are assigned negative PLS coefficients of 0.26, 
0.24 and 0.11, respectively (Figure 4b). For DHQ2-Mt, in 
addition to the equivalent residues, Leu13, Gly77 and Ile102, 
Leu16 is also identified and negative PLS coefficients of 0.23, 
0.38, 0.28 and 0.15, respectively, are assigned to them 
(Figure 4d). In general, the contribution of van der Waals 
interactions with these residues to the inhibitory potencies is 
greater than those corresponding to residues at the interface 
pocket, as reflected by the PLS coefficients obtained, in particular 
those related to Leu14 and Gly78 for DHQ2-Hp, and Ile102 and 
Gly77 for DHQ2-Mt. These results justify the high inhibitory 
potency of the natural substrate analogs substituted at C2 with a 
benzyl group in the equatorial position.[6] It is worth mentioning 
that these compounds still contain the axial hydrogen that could 
be removed by the essential tyrosine. The PLS coefficients 
assigned to Ile102 (0.28) in DHQ2-Mt is more than twice the 
value assigned to the equivalent Leu103 in DHQ2-Hp (0.11). In 
principle, the structural differences between the two enzymes in 
this region of the active site are small and do not justify the 
observed differences. However, because this apolar pocket is 
generated as a result of the closure of the loop upon substrate or 
inhibitor binding, the distinct flexibility and motion of the loops in 
the two enzymes are likely to account for these differences. 
Essential water molecule. Our results show that the electrostatic 
and hydrogen bonding interactions of the inhibitors with the water 
molecule involved in the enzymatic mechanism, which orients the 
natural substrate and the intermediate in the active site, 
contribute favorably to potency against both enzymes. In fact, this 
is the van der Waals interaction (hydrogen bonding) with the 
highest negative PLS coefficients values (0.45 and 0.56, for 
DHQ2-Hp and DHQ2-Mt enzymes, respectively). These results 
quantify the experimental observation that the replacement of the 
oxygen atom of the 3-methoxyaryl enol mimetics by a carbon 
atom leads to a decrease in the inhibition potency of up to 20-fold 
(supporting information, Table S1, entry 1).[17] Our chemometric 
studies quantitate how important this contact is for modulating the 
potency of the inhibitors and reveal that it is worth considering in 
future medicinal chemistry designs. 
On the other hand, for DHQ2-Mt, a favorable hydrogen bonding 
interaction with a water molecule observed in several crystal 
structures is identified. This water molecule is located very close 
to the essential Tyr24 and the conserved Arg108. For instance, in 
PDB entry 2Y71[8] solved at 1.5 Å, this water molecule is 2.5 Å 
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and 2.9 Å away from Tyr24 and Arg108, respectively. We 
consider that this result reveals once again the importance of the 
inappropriate orientation of Tyr24 for proton abstraction and 
therefore for good enzyme inhibition. 
C1 binding pocket. These COMBINE analyses reveal that the 
hydrogen bonding interaction between the ligands and the 
essential histidine, His102 for DHQ2-Hp and His101 for DHQ2-Mt, 
is also important for modulating the inhibitory potency against 
both enzymes, as attested by the negative PLS coefficients of 
0.13 and 0.16, respectively. This residue is involved in the final 
elimination step by acting as the general acid with a conserved 
asparagine, Asn76 for DHQ2-Hp and Asn75 for DHQ2-Mt, and 
correctly positioning the C1 hydroxyl group to accept a proton. 
For the latter enzyme, a negative PLS coefficient value of 0.22 
was also obtained for the favorable hydrogen-bonding interaction 
with Asn75. For a long time, it has been suggested that the C1 
binding pocket plays a crucial role in ligand recognition. In fact, it 
is believed that the driving force for product release during 
catalysis is the conformational change in the product as the C1 
atom becomes planar.[5] The present COMBINE analyses show 
that DHQ2-Mt is particularly sensitive to small conformational 
changes in the inhibitor because they may change the correct 
positioning of the C1 hydroxyl group for hydrogen bonding. 
 
   
   
Figure 4. A detailed view of the key residues that contribute most significantly to explaining the differences in inhibitory potency, as revealed by the COMBINE 
analysis: DHQ2-Hp (a and b) and DHQ2-Mt (c and d). Figures a and c show the interface pocket between two symmetry-related neighboring chains close to the 
enzyme active site. Note how there are important differences regarding the type of residues lining this pocket in both enzymes. Side chains of relevant residues are 
shown and labeled. 
Conclusions and Final Remarks 
Two COMBINE analyses have been conducted to quantify the 
contribution of each active site residue to inhibition of the type II 
dehydroquinases from H. pylori and M. tuberculosis by a large 
series of compounds spanning more than four orders of 
magnitude in inhibition constants. The best models attained 
acceptable figures of merit, as assessed by correlation 
coefficients, r2, of 0.83 and 0.88 and cross-validated correlation 
coefficients, q2, of 0.73 and 0.71, respectively. 
The QSAR model for DHQ2-Hp identifies the van der Waals 
interactions with Asn10, Met13, Leu14, Tyr22, Leu103, His102 
and Gly78, and Gln63* and Ala90* of a symmetry-related 
neighboring subunit, as well as the electrostatic and hydrogen 
bonding interactions with the essential water molecule, as those 
that contribute more significantly to explaining the differences in 
inhibitory potency. For DHQ2-Mt, the model is dominated by van 
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der Waals interactions with active site residues Tyr24, Leu13, 
Leu16, Ile102, Gly77, Asn75 and His101, and with Ala91* and 
Glu92* of the neighboring subunit, as well as by electrostatic 
and/or by hydrogen bonding interactions with the essential water 
molecule and the crystallographic water molecule close to Arg108 
and Tyr24. 
It is noteworthy that, for both enzymes, the COMBINE highlight 
the importance of the water molecule involved in the enzymatic 
mechanism, which fixes the natural substrate and the 
intermediate in the active site. A second key contribution in the 
inhibition activity is the C2 binding pocket, particularly for DHQ2-
Mt, which involves residues Leu13, Leu16, Ile102 and Gly77. In 
addition, significant differences between both enzymes are 
detected in the way the inhibitors interact with the essential 
tyrosine, the residue that initiates enzymatic catalysis. We 
consider that these differences arise from differences in loop 
flexibility and motion between the two enzymes. 
Finally, the COMBINE approach has allowed us to quantify the 
importance of ligand interactions at the interface pocket close to 
the active site, to highlight the key differences between both 
enzymes and to provide guidance for further inhibitor design. 
Thus, for DHQ2-Hp, enzyme inhibition might be enhanced by 
promoting interactions between the ligand and residues Gln63* 
and Ala90*, which are located at the “bottom” of the interface, and 
avoiding contacts with residues Asp89* and Leu93*, which are 
located at the “upper part” of the interface. On the other hand, for 
DHQ2-Mt, improving the van der Waals interactions with Glu92*, 
a residue located at the entrance to the interface, might provide 
more potent inhibitors. For both enzymes, extending the contacts 
with Asp88*, which is involved in the recognition of the hydroxyl 
group at the C4 position in both the natural substrate and the 
reaction intermediate, would be unfavorable. 
Experimental Section 
Ligand minimization. Initial ligand geometries were first refined by 
using the PM6 hamiltonian, as implemented in Gaussian 09,
[40]
 and 
further energy-minimized using a restricted Hartree–Fock (RHF) 
method and a 6–31G(d) basis set while fixating the three dihedral 
angles defining the orientation of the carboxylate group and the 
hydroxyl groups at C1 and C5. The charge distribution for all the 
ligands was obtained by fitting the electrostatic potential-derived 
(ESP) atom-centered charges as implemented in Gaussian 09, to a 
restrained electrostatic potential (RESP)
[41,42]
 point-charge model, as 
implemented in AMBER
[43]
 suite of programs using a polarizable 
continuum model of solvation. The missing bonded and non-bonded 
parameters were assigned, by analogy or through interpolation from 
those already present in the AMBER database (GAFF). 
Minimization of crystallographic DHQ2-ligand binary complexes. 
These studies were carried out using the enzyme geometries found in 
several crystal structures of the binary complexes DHQ2-Hp and 
DHQ2-Mt. For the former enzyme, eight crystal structures were used 
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. Considering that, to guarantee a successful 
COMBINE analysis, all the proteins employed must have exactly the 
same number of residues, not solved residues were incorporated 
from the fully resolved crystal structures, i.e. 2WKS
[7]
 for DHQ2-Hp 
and 2XB8
[23] 
for DHQ2-Mt. With the exception of two water molecules 
located in the active site, all the other water molecules and the 
cocrystallized molecules originating from the enzyme storage buffer 
(TRIS, glycerol, sulfate, etc.) were removed from the complexes. This 
water molecules are the conserved one (WATe) involved in the 
enzymatic mechanism and a crystallographic water molecule (WATc) 
located near the essential tyrosine and the conserved arginine, i.e. 
Arg109, for DHQ2-Hp, and Arg108, for DHQ2-Mt. First, energy 
minimization of the crystallographic DHQ2-ligand binary complexes 
used in this study was performed using the Generalized Born (GB) 
solvation model (igb = 1) with no cutoff for non-bonded interactions 
(cut = 999), no periodic boundary conditions (ntb = 0) and the 
steepest descent algorithm. Taking into account that unfolding and 
refolding studies on DHQ2 have shown that the trimer
[44]
 is the 
biological unit of the enzyme, the trimer was used for these studies. 
Hydrogens were added to the protein using the web-based 
PROPKA3.1 server,
[45-48]
 which assigned protonation states to all 
titratable residues at the chosen pH of 7.0. However, δ and/or ε 
protonation was manually corrected for His101/His102 (dual) of the 
active site due to mechanistic considerations and the fact that 
PROPKA does not consider any bound ligand in the calculation. 
Molecular mechanics parameters from the ff03 and GAFF force fields 
were assigned to the protein and waters and to the ligand, 
respectively. Energy minimizations were performed using the Sander 
program of AMBER 10. The positions of hydrogens were first 
optimized in vacuo by running 500 steps of steepest descent followed 
by 500 steps of conjugate gradient energy minimization. Protein side-
chain optimization then followed by performing 1000 steps of steepest 
descent followed by 1000 steps of conjugate gradient energy 




 was used for 
positionally restraining all the atoms not subjected to energy 
refinement. Finally, the entire complex was adapted to the force field 
by performing 1000 steps of steepest descent followed by 1000 steps 
of conjugate gradient energy minimization. 
Minimization of the DHQ2-ligand complexes. Bound ligands in the 
energy-minimized crystallographic binary complexes were replaced 
by the set of congeneric inhibitors (supporting information) and 
aligned. Energy optimization of each complex was achieved by using 
the steepest descent algorithm and the GB implicit solvent model until 






COMBINE analysis. AMBER coordinate and topology files for the set 
of refined ligand-enzyme complexes containing two water molecules 
as explained above, were directly used as input to the gCOMBINE 
program.
[49]
 The inhibitory activity data for the set of inhibitors that are 
available as Ki values (expressed in molar units, supporting 
information), were converted to negative logarithmic values (i.e., pKi), 
which range from 3.4 to 7.0 for DHQ2-Hp and from 3.7 to 7.6 for 
DHQ2-Mt. The interaction energy matrix was then subjected to partial 
least squares (PLS) analysis using the pKi values as the experimental 
observables, the leave-one-out method for cross-validation and a 
uniform dielectric constant of 4.0 to calculate the electrostatic 
interactions. Any positive van der Waals energy value was truncated 
to 0.0 kcal mol
-1
 and any variable with a standard deviation below 0.1 
kcal mol
-1
 within the series was removed. The quality of the models 
was assessed by the correlation coefficient (r
2
) and the cross-
validated correlation coefficient (q
2
).  
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Interactions driving inhibition: 
Quantitative-activity relationship 
studies conducted with type II 
dehydroquinase inhibitors from H. 
pylori and M. tuberculosis supports 
the importance of the hydrogen 
bonding interaction of the inhibitors 
with the water molecule involved in 
the enzymatic mechanism and 
identified important differences in the 
ligand interactions with the interface 
pocket close to the active site for both 
enzymes. 
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